These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 36353641)

  • 1. Advancing mRNA technologies for therapies and vaccines: An African context.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Front Immunol; 2022; 13():1018961. PubMed ID: 36353641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines on demand, part II: future reality.
    Geall AJ; Kis Z; Ulmer JB
    Expert Opin Drug Discov; 2023 Feb; 18(2):119-127. PubMed ID: 36384351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic modified messenger RNA for therapeutic applications.
    Gao M; Zhang Q; Feng XH; Liu J
    Acta Biomater; 2021 Sep; 131():1-15. PubMed ID: 34133982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New Hopes in Vaccine Technology: mRNA Vaccines].
    Yılmaz E
    Mikrobiyol Bul; 2021 Apr; 55(2):265-284. PubMed ID: 33882657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 mRNA vaccines: Platforms and current developments.
    Szabó GT; Mahiny AJ; Vlatkovic I
    Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative Strategies to Enhance mRNA Vaccine Delivery and Effectiveness: Mechanisms and Future Outlook.
    Verma A; Awasthi A
    Curr Pharm Des; 2024; 30(14):1049-1059. PubMed ID: 38551046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives and Prospects on mRNA Vaccine Development for COVID-19.
    Jin L; Han Z; Zhao P; Sun K
    Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
    Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
    J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate immune mechanisms of mRNA vaccines.
    Verbeke R; Hogan MJ; Loré K; Pardi N
    Immunity; 2022 Nov; 55(11):1993-2005. PubMed ID: 36351374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines.
    Matsumura T; Takano T; Takahashi Y
    Int Immunol; 2023 May; 35(5):213-220. PubMed ID: 36566501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across.
    Minnaert AK; Vanluchene H; Verbeke R; Lentacker I; De Smedt SC; Raemdonck K; Sanders NN; Remaut K
    Adv Drug Deliv Rev; 2021 Sep; 176():113900. PubMed ID: 34324884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA delivery technologies: Toward clinical translation.
    Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
    Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
    Kana BD; Arbuthnot P; Botwe BK; Choonara YE; Hassan F; Louzir H; Matsoso P; Moore PL; Muhairwe A; Naidoo K; Ndomondo-Sigonda M; Madhi SA
    Lancet Infect Dis; 2023 Aug; 23(8):e288-e300. PubMed ID: 37290473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-amplifying mRNA vaccines: Mode of action, design, development and optimization.
    Pourseif MM; Masoudi-Sobhanzadeh Y; Azari E; Parvizpour S; Barar J; Ansari R; Omidi Y
    Drug Discov Today; 2022 Nov; 27(11):103341. PubMed ID: 35988718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19.
    Silva-Pilipich N; Beloki U; Salaberry L; Smerdou C
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine process technology-A decade of progress.
    Buckland B; Sanyal G; Ranheim T; Pollard D; Searles JA; Behrens S; Pluschkell S; Josefsberg J; Roberts CJ
    Biotechnol Bioeng; 2024 Sep; 121(9):2604-2635. PubMed ID: 38711222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.